The estimated Net Worth of Xiaodong Wang is at least $67.2 Million dollars as of 8 March 2023. Xiaodong Wang owns over 67,635 units of BeiGene Ltd stock worth over $14,281,130 and over the last 8 years he sold BGNE stock worth over $46,268,875. In addition, he makes $6,627,000 as Co-Founder and Non-Executive Director at BeiGene Ltd.
Sign up
Xiaodong Wang BGNE stock SEC Form 4 insiders trading
Xiaodong has made over 37 trades of the BeiGene Ltd stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 67,635 units of BGNE stock worth $8,793 on 8 March 2023.
The largest trade he's ever made was selling 93,750 units of BeiGene Ltd stock on 23 November 2016 worth over $3,000,000. On average, Xiaodong trades about 10,106 units every 41 days since 2016. As of 8 March 2023 he still owns at least 67,635 units of BeiGene Ltd stock.
You can see the complete history of Xiaodong Wang stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Xiaodong Wang biography
Dr. Xiaodong Wang Ph.D. serves as Co-Founder, Non-Executive Director of the Company. He is our Co-Founder and has served as a member of our Board of Directors since February 2016. He has also served as the Chairman of our Scientific Advisory Board since 2011. Dr. Wang has served as the founding Director of the National Institute of Biological Sciences in Beijing since 2003 and became its Director and Investigator in 2010. Previously, he was a Howard Hughes Medical Institute Investigator from 1997 to 2010 and held the position of the George L. MacGregor Distinguished Chair Professor in Biomedical Sciences at the University of Texas Southwestern Medical Center in Dallas, Texas from 2001 to 2010. In 2004, Dr. Wang founded Joyant Pharmaceuticals, Inc., a venture capital-backed biotechnology company focused on the development of small molecule therapeutics for cancer. Dr. Wang received his B.S. in Biology from Beijing Normal University in July 1984 and his Ph.D. in Biochemistry from the University of Texas Southwestern Medical Center in May 1991. Dr. Wang has been a member of the National Academy of Science, USA since 2004 and a foreign associate of the Chinese Academy of Sciences since 2013. Wang’s extensive experience in cancer drug research, combined with his experience in the biotech industry, qualify him to serve as a member of our Board of Directors.
What is the salary of Xiaodong Wang?
As the Co-Founder and Non-Executive Director of BeiGene Ltd, the total compensation of Xiaodong Wang at BeiGene Ltd is $6,627,000. There are 1 executives at BeiGene Ltd getting paid more, with John Oyler having the highest compensation of $13,899,000.
How old is Xiaodong Wang?
Xiaodong Wang is 57, he's been the Co-Founder and Non-Executive Director of BeiGene Ltd since 2016. There are 8 older and 12 younger executives at BeiGene Ltd. The oldest executive at BeiGene Ltd is Donald Glazer, 75, who is the Non-Executive Independent Director.
What's Xiaodong Wang's mailing address?
Xiaodong's mailing address filed with the SEC is C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN, E9, KY1-1108.
Insiders trading at BeiGene Ltd
Over the last 9 years, insiders at BeiGene Ltd have traded over $1,899,158,980 worth of BeiGene Ltd stock and bought 23,241,738 units worth $1,040,248,444 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Investment Management, Ltd...., and Bros. Advisors Lp Baker Bro.... On average, BeiGene Ltd executives and independent directors trade stock every 13 days with the average trade being worth of $33,382,815. The most recent stock trade was executed by Xiaobin Wu on 3 September 2024, trading 5,556 units of BGNE stock currently worth $1,053,695.
What does BeiGene Ltd do?
BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.
What does BeiGene Ltd's logo look like?
Complete history of Xiaodong Wang stock trades at BeiGene Ltd
BeiGene Ltd executives and stock owners
BeiGene Ltd executives and other stock owners filed with the SEC include:
-
John Oyler,
Co-Founder, Executive Chairman of the Board, Chief Executive Officer -
Xiaodong Wang,
Co-Founder, Non-Executive Director -
Dr. Xiaodong Wang Ph.D.,
Co-Founder, Chairman of the Scientific Advisory Board & Non-Exec. Director -
John V. Oyler,
Co-Founder, Exec. Chairman & CEO -
Dr. Xiaobin Wu Ph.D.,
Pres, COO & GM of China -
Wang Lai,
Global Head of R&D -
Dr. Edna Huang M.D.,
Chief Medical Officer of Hematology -
Dr. Jane Edna Huang M.D.,
Chief Medical Officer of Hematology -
Dr. Heng Liang,
CFO & Chief Strategy Officer -
Thomas Malley,
Non-Executive Independent Director -
Qingqing YI,
Non-Executive Independent Director -
Timothy Chen,
Non-Executive Independent Director -
Jing-Shyh Su,
Non-Executive Independent Director -
Donald Glazer,
Non-Executive Independent Director -
Ranjeev Krishana,
Non-Executive Independent Director -
Michael Goller,
Non-Executive Independent Director -
Corazon Sanders,
Non-Executive Independent Director -
Anthony Hooper,
Non-Executive Director -
Hing Ling Chau,
Company Secretary -
Jane Huang,
Chief Medical Officer, Hematology -
Xiaobin Wu,
General Manager - China, President -
Kevin C. Mannix,
Sr. VP of Investor Relations. -
Mi Zhou,
Sr. Director of Investor Relations -
Julia Wang,
CFO & Principal Accounting Officer -
Diana Lee Francis,
VP and Global Head of Quality & Regulatory Compliance -
Scott Samuels,
Sr. VP & Gen. Counsel -
Craig West CFA,
Sr. Director of Investor Relations -
Michael Garvey,
Global Head of Technical Operations -
Daniel Maller,
VP of Fin. & Accounting -
Jianxin Yang,
Sr. VP, Head of Clinical Dev. -
Amy C. Peterson,
CMO, Immuno-oncology -
Ji Li,
EVP and Gl. Head of Bus. Dev. -
Investment Management, Ltd....,
10% owner -
Rui Rong Yuan,
Chief Medical Officer -
Ke Tang,
Director -
Bros. Advisors Lp Baker Bro...,
-
Biotech Investment Ltd Cpe ...,
-
Wendy Xiaojun Yan,
Sr. VP, Head of Reg. Affairs -
& Co., Inc.Merck Sharp & Do...,
-
Chan Henry Lee,
SVP, General Counsel -
Bros. Advisors Lp14159, L.P...,
-
Bros. Advisors Lp667, L.P.B...,
-
Howard Liang,
CFO & Chief Strategy Officer -
Inc Amgen,
10% owner -
Lai Wang,
Global Head of R&D -
Olivier Brandicourt,
Director -
Julia Aijun Wang,
Chief Financial Officer -
Margaret Dugan,
Director -
Advisors, Ltd.Hillhouse Inv...,
-
Bros. Advisors Lp667, L.P.B...,
-
Titus B. Ball,
Principal Accounting Officer -
Aaron Rosenberg,
Chief Financial Officer